• +91 96866 96505
  • OncoStem Diagnostics Pvt Ltd

Importance of Prognostic Testing in Breast Cancer

Tailored Treatment Plan

Prognostic test, like CanAssist Breast, helps personalize treatment strategies based on the aggressive biology of the tumor and the likelihood of recurrence, ensuring patients receive the optimal treatment with minimum side effects.

Improved Patient Outcomes

By understanding cancer behavior at the cellular/molecular level, prognostic testing helps optimize treatment decisions, leading to better outcomes and more efficient use of healthcare resources.

about
  • Focus on Personalized Treatment

  • New Advanced Instruments

  • Expertise in Tumor Biology

CanAssist Breast: From India for the world—bringing innovation in breast cancer prognosis globally

In the era of precision medicine, OncoStem aims to deliver cutting-edge technology to assist physicians in providing cost-effective, personalized treatment choices for cancer patients. OncoStem’s team of scientists has developed innovative one-of-a-kind multi-marker prognostic test for breast cancer- CanAssist Breast- that provides information regarding a patient’s cancer recurrence risk.

CanAssist Breast (CAB) uses a combination of proteomics and an AI-based approach. CAB assesses the expression of five cancer biomarkers using an automated IHC platform and further integrates it with clinical parameters in a proprietary AI-based algorithm to determine the risk of distant cancer recurrence in patients. This pioneering test, made in India in 2016, has since expanded its reach across multiple countries, including India, Turkey, UAE, Saudi Arabia, Sri Lanka, Bangladesh, and Iran, helping clinicians worldwide make informed decisions for personalized breast cancer treatment.

Why Get Tested?
  • Know Your Recurrence Risk

  • Personalize Your Cancer Treatment

  • Avoid Chemotherapy and it's Side Effects

Scientific Publications

Comparison of Risk Stratification by CanAssist Breast Test Performed on Core Needle Biopsies Versus Surgical Specimens in Hormone Receptor-Positive, Her2-Negative Early Breast Cancer

Cureus Part of Springer Nature

The usefulness of CanAssist Breast over Ki67 in breast cancer recurrence risk assessment

Cancer Medicine

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial

Breast Cancer Research

A comparative analysis of recurrence risk predictions in ER+/HER2−early breast cancer using CanAssist Breast & PREDICT

Breast Cancer Reserve and Treatment

News & Updates

post image

OncoStem Diagnostics and Dr. Manjiri Bakre in the news

Women’s Entrepreneur Review; Women Leaders In Healthcare Publication Date: October 2024 Issue

+ Read More
Sign Up For Alerts, News, Thoughts, And Insights
Have A Question! Contact Us

Press & Media Coverage

backgrounds

Helping To Deliver Answers For Health Questions!

The Science Behind CanAssist Breast: Biomarker Analysis

CanAssist Breast employs a comprehensive biomarker analysis technique to arrive at its prognostic score. This process delves into the complex molecular structure of the patient's tumor, enabling a more personalized approach to breast cancer management.

Know More

Comprehensive Biomarker Analysis

CanAssist Breast evaluates multiple biomarkers in the tumor tissue, providing a deeper understanding of the tumor's specific characteristics for personalized treatment.

Risk Score Calculation

The test generates a risk score based on biomarker data, predicting the likelihood of cancer recurrence within five years, allowing for tailored treatment strategies.

Avoidance of Over-Treatment

By identifying low-risk patients, CanAssist Breast helps avoid unnecessary aggressive treatments, reducing side effects and healthcare costs.

Timely Aggressive Therapy for High-Risk Patients

The test ensures that high-risk patients receive aggressive therapies at the appropriate time, improving their chances of successful treatment.